BCL2L1 and Thrombocytopenia: A major drawback of earlier BH3 mimetics targeting multiple Bcl-2 proteins, such as navitoclax, was their on-target/off-tumor inhibition of Bcl-xL in platelets, resulting in dose-limiting thrombocytopenia [38].